The announcement comes as researchers have noted that the pandemic has begun shifting from urban centers like New York to rural areas of the country. The U.S. continues to lead the world in SARS-CoV-2 infections, with more than 1.5 million cases as of Thursday.
Drugmakers, medical research groups and healthcare companies and organizations are at risk of "password spraying" attacks by state-sponsored hackers, the officials said in a joint statement.
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Bloomberg reported Wednesday that the Trump administration is launching the effort, which it compared to the Manhattan Project, to shorten the length of time it would take to develop a vaccine for the disease.
A preprint retrospective analysis among 368 patients hospitalized with Covid-19 in the VA system found no benefit and a higher degree of death from hydroxychloroquine. A panel of experts also recommended against using the drug with azithromycin outside of trials due to potential toxicity.
More than 80,000 people worldwide have been infected with the SARS-CoV-2 virus. In response, the U.S. government has partnered with several companies to develop drugs to treat the infection and vaccines to prevent it.
The Senate voted 72-18 Thursday to confirm Hahn, a radiation oncologist and chief medical executive at The University of Texas MD Anderson Cancer Center.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
Five Democratic senators - two running for president - wrote in a letter to the FDA's acting commissioner that the scandal highlighted industry "privilege and greed."
On a quarterly basis, companies in areas like cell and gene therapy raised less in the second quarter than during the same period last year, but the number of clinical trials underway saw an uptick. European and Israeli firms also saw a boost in funding.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The administration's plan to lower drug costs met two major setbacks last week. Experts weighed in on what that could mean.
Amgen, Eli Lilly and Merck - plus the Association of National Advertisers - said in a complaint filed Friday that the law would mislead consumers, overstep the government's authority and violate the First Amendment.
The changes will take place 60 days after the rule is published in the Federal Register. Industry trade group PhRMA have opposed the rule, saying it will lead to consumer confusion and sticker shock that could discourage medication use.
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
The agency also proposed increasing the maximum new technology add-on payment from 50 percent to 65 percent for fiscal year 2020.